Pharmacology of bismuth-containing compounds.
Bismuth compounds have been used for more than two centuries. A review of the modes of action, pharmacokinetics, and toxicity of two commonly used compounds, colloidal bismuth subcitrate and bismuth subsalicylate, is presented. In humans bismuth toxicity is unlikely when therapeutic doses of these compounds are administered for the appropriate duration. The recent use of bismuth compounds to eradicate infection with Helicobacter pylori and to prevent travelers' diarrhea has resulted in scientific reevaluation of these agents.
Lambert
J R
JR
Department of Medicine, Prince Henry's Hospital, Melbourne, Victoria, Australia.
D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001729:Bismuth / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D006801:Humans; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D012459:Salicylates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; C002791:bismuth tripotassium dicitrate; D001729:Bismuth